Microvast Holdings announces departure of chief financial officer
Dyadic International , Inc. (NASDAQ:DYAI) announced Wednesday it received a notice from the Nasdaq Stock Market LLC indicating that the company’s common stock failed to maintain the minimum bid price of $1 per share over the past 30 consecutive business days, as required by Nasdaq Listing Rule 5550(a)(2).
The notice, dated July 17, 2025, does not immediately affect the listing of Dyadic’s common stock on the Nasdaq Capital Market. According to the company’s statement, Dyadic has 180 calendar days, or until January 13, 2026, to regain compliance. To do so, the company’s common stock must close at $1 per share or higher for at least 10 consecutive business days before the compliance deadline. Nasdaq may, at its discretion, extend this period.
If Dyadic does not regain compliance by January 13, 2026, it may be eligible for an additional 180-day period to meet the requirement, provided it satisfies other continued listing criteria, including the market value of publicly held shares. Should the company remain non-compliant after these periods, Nasdaq staff may issue a written notification that the company’s common stock is subject to delisting. Dyadic would then have the opportunity to appeal the determination to a hearings panel.
The company stated it intends to monitor the bid price of its common stock and evaluate available options to resolve the deficiency.
Dyadic also remains out of compliance with the minimum market value of listed securities requirement of $35 million under Nasdaq Listing Rule 5550(b)(2), with a deadline of December 20, 2025, to regain compliance. The company noted that the bid price deficiency is separate from the market value deficiency, and failure to address either could result in delisting. With a current market capitalization of $32.8 million, the company needs to bridge a modest gap to meet the listing requirement. For deeper insights into Dyadic’s financial health and future prospects, investors can access comprehensive analysis and additional metrics through InvestingPro’s detailed research reports.
This information is based on a press release statement included in Dyadic International’s Form 8-K filing with the Securities and Exchange Commission.
In other recent news, Dyadic International Inc. reported its first-quarter 2025 financial results, showing a net loss of $0.07 per share, which met expectations. The company’s revenue was $393,570, slightly below the forecast of $394,000. Dyadic has announced a strategic rebranding to Dyadic Applied BioSolutions, reflecting a shift from research to commercial operations, focusing on non-therapeutic proteins for various applications. Additionally, the company appointed Joe Hazelton as its new President to lead this strategic shift, while he continues as Chief Operating Officer. Hazelton’s appointment is supported by the Board of Directors, aligning with Dyadic’s focus on commercializing recombinant protein products. Shareholders recently approved board proposals at the annual meeting, electing Mark A. Emalfarb as a Class III director. These developments highlight Dyadic’s efforts to capitalize on commercial growth opportunities in high-demand sectors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.